Sandoz demonstrated strong sales growth and strategic advancements, particularly in the biosimilars segment, and successfully transitioned to an independent company. However, financial challenges such as negative free cash flow and decreased core EBITDA margin due to high costs and currency impacts present notable concerns.

Company Guidance

During the earnings call for the fourth quarter of 2023, Sandoz provided several key metrics and guidance for the upcoming year. The company reported a 10% increase in fourth-quarter sales, reaching $2.5 billion, with full-year sales growing 7% to $9.6 billion. This growth was driven by a 26% increase in biosimilar sales and a 6% rise in generics, supported by volume gains and lower-than-expected price erosion. Sandoz's core EBITDA for 2023 was $1.7 billion, representing an 18.1% margin, despite challenges from inflation and foreign exchange impacts. The company expects mid-single-digit net sales growth in constant currencies for 2024 and aims to increase its core EBITDA margin to around 20%. Sandoz also plans to focus on operational efficiencies and biosimilar launches to sustain growth and expand margins, projecting biosimilars to account for 30% of sales by 2028.

Strong Regional Performance

North American sales were up 20% in Q4 2023, marking a significant return to growth, driven by strong biosimilar performance and strategic pipeline rebuilding.

Biosimilars Growth

Biosimilars sales grew by 26% in Q4 and 15% for the full year, with key contributors being Omnitrope and the launch of Hyrimoz in the U.S.

Successful Spin-Off

Completed a successful spin from the former parent company, secured long-term financing, and ensured business continuity as an independent public company.

Strategic Acquisitions and Partnerships

Acquired CIMERLI to expand the U.S. retina market presence and entered a multiyear agreement with Cordavis to expand Hyrimoz reach.

Environmental and Sustainability Commitments

Submitted a commitment letter to the Science Based Targets Initiative to set carbon emission reduction targets in line with the Paris Agreement.

---

Sandoz Group Ltd Sponsored ADR (SDZNY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SDZNY Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 13, 2024	2023 (Q4)	- / -	―	―
Aug 08, 2024	2024 (Q2)	- / 0.35	―	―
Mar 05, 2025	2024 (Q4)	- / -	―	―	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

SDZNY Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 08, 2024	$41.29	$40.39	-2.18%
Mar 13, 2024	$31.62	$32.63	+3.19%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---

FAQ

When does Sandoz Group Ltd Sponsored ADR (SDZNY) report earnings?

Sandoz Group Ltd Sponsored ADR (SDZNY) is schdueled to report earning on Mar 05, 2025, TBA Not Confirmed.

What is Sandoz Group Ltd Sponsored ADR (SDZNY) earnings time?

Sandoz Group Ltd Sponsored ADR (SDZNY) earnings time is at Mar 05, 2025, TBA Not Confirmed.

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is SDZNY EPS forecast?

Currently, no data Available

---

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing